Endothelin and podocyte injury in chronic kidney disease

Endothelin in Renal Physiology and Disease

Volumn 172, Issue , 2011, Pages 120-138

  Fligny, Cécile ^a   Barton, Matthias ^b   Tharaux, Pierre Louis ^a  

^a INSERM   (France)

^b UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTHELIN; ENDOTHELIN RECEPTOR;

ANIMAL; CHRONIC DISEASE; GLOMERULONEPHRITIS; HUMAN; IMMUNOGLOBULIN A NEPHROPATHY; KIDNEY DISEASE; PHYSIOLOGY; PODOCYTE; REVIEW;

ANIMALS; CHRONIC DISEASE; ENDOTHELINS; GLOMERULONEPHRITIS; GLOMERULONEPHRITIS, IGA; HUMANS; KIDNEY DISEASES; PODOCYTES; RECEPTORS, ENDOTHELIN;

EID: 84926111700     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1159/000328692     Document Type: Chapter

References (105)

1. Dimitrov BD, Perna A, Ruggenenti P, Remuzzi G: Predicting end-stage renal disease: Bayesian perspective of information transfer in the clinical decision-making process at the individual level. Kidney Int 2003;63:1924-1933.
2. Lemley KV, Blouch K, Abdullah I, Boothroyd DB, Bennett PH, Myers BD, Nelson RG:Glomerular permselectivity at the onset of nephropathy in type 2 diabetes mellitus. J Am Soc Nephrol 2000;11:2095-2105.
3. Andersen S, Blouch K, Bialek J, Deckert M, Parving HH, Myers BD: Glomerular permselectivity in early stages of overt diabetic nephropathy. Kidney Int 2000;58:2129-2137.
4. Pavenstadt H, Kriz W, Kretzler M: Cell biology of the glomerular podocyte. Physiol Rev 2003;83(1):253-307.
5. Lambers Heerspink HJ, Brantsma AH, de Zeeuw D, Bakker SJ, de Jong PE, Gansevoort RT: Albuminuria assessed from first-morning-void urine samples versus 24-hour urine collections as a predictor of cardiovascular morbidity and mortality. Am J Epidemiol 2008;168:897-905.
6. Reffelmann T, Dorr M, Volzke H, Friedrich N, Krebs A, Ittermann T, Felix SB: Urinary albumin excretion, even within the normal range, predicts an increase in left ventricular mass over the following 5 years. Kidney Int 2010;77:1115-1122.
7. Solomon SD, Lin J, Solomon CG, Jablonski KA, Rice MM, Steffes M, Domanski M, Hsia J, Gersh BJ, Arnold JM, Rouleau J, Braunwald E, Pfeffer MA: Influence of albuminuria on cardiovascular risk in patients with stable coronary artery disease. Circulation 2007;116:2687-2693.
8. Nobakhthaghighi N, Kamgar M, Bekheirnia MR, McFann K, Estacio R, Schrier RW:Relationship between urinary albumin excretion and left ventricular mass with mortality in patients with type 2 diabetes. Clin J Am Soc Nephrol 2006;1:1187-1190.
9. Perkovic V, Verdon C, Ninomiya T, Barzi F, Cass A, Patel A, Jardine M, Gallagher M, Turnbull F, Chalmers J, Craig J, Huxley R:The relationship between proteinuria and coronary risk: a systematic review and metaanalysis. PLoS Med 2008;5:e207.
10. Jackson CE, Solomon SD, Gerstein HC, Zetterstrand S, Olofsson B, Michelson EL, Granger CB, Swedberg K, Pfeffer MA, Yusuf S, McMurray JJ: Albuminuria in chronic heart failure: prevalence and prognostic importance. Lancet 2009;374:543-550.
11. van der Velde M, Matsushita K, Coresh J, Astor BC, Woodward M, Levey A, de Jong P, Gansevoort RT, Levey AS, de Jong PE, El-Nahas M, Eckardt KU, Kasiske BL, Ninomiya T, Chalmers J, Macmahon S, Tonelli M, Hemmelgarn B, Sacks F, Curhan G, Collins AJ, Li S, Chen SC, Hawaii Cohort KP, Lee BJ, Ishani A, Neaton J, Svendsen K, Mann JF, Yusuf S, Teo KK, Gao P, Nelson RG, Knowler WC, Bilo HJ, Joosten H, Kleefstra N, Groenier KH, Auguste P, Veldhuis K, Wang Y, Camarata L, Thomas B, Manley T: Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts. Kidney Int 2011;79:1341-1352.
12. Warnock DG, Muntner P, McCullough PA, Zhang X, McClure LA, Zakai N, Cushman M, Newsome BB, Kewalramani R, Steffes MW, Howard G, McClellan WM: Kidney function, albuminuria, and all-cause mortality in the REGARDS (Reasons for Geographic and Racial Differences in Stroke) study. Am J Kidney Dis 2010;56:861-871.
13. Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, de Jong PE, Coresh J, Gansevoort RT: Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 2010;375:2073-2081.
14. Faul C, Asanuma K, Yanagida-Asanuma E, Kim K, Mundel P: Actin up: regulation of podocyte structure and function by components of the actin cytoskeleton. Trends Cell Biol 2007;17:428-437.
15. Shankland SJ: The podocyte's response to injury: role in proteinuria and glomerulosclerosis. Kidney Int 2006;69:2131-2147.
16. Kriz W: The role of the podocyte in the degeneration of a renal glomerulus. Adv Nephrol Necker Hosp 1997;27:1-13.
17. Petermann A, Floege J: Podocyte damage resulting in podocyturia: a potential diagnostic marker to assess glomerular disease activity. Nephron Clin Pract 2007;106:c61-66.
18. Meyer TW, Bennett PH, Nelson RG:Podocyte number predicts long-term urinary albumin excretion in Pima Indians with type II diabetes and microalbuminuria. Diabetologia 1999;42:1341-1344.
19. Ortmann J, Amann K, Brandes RP, Kretzler M, Munter K, Parekh N, Traupe T, Lange M, Lattmann T, Barton M: Role of podocytes for reversal of glomerulosclerosis and proteinuria in the aging kidney after endothelin inhibition. Hypertension 2004;44:974-981.
20. Morigi M, Buelli S, Angioletti S, Zanchi C, Longaretti L, Zoja C, Galbusera M, Gastoldi S, Mundel P, Remuzzi G, Benigni A: In response to protein load podocytes reorganize cytoskeleton and modulate endothelin-1 gene: implication for permselective dysfunction of chronic nephropathies. Am J Pathol 2005;166:1309-1320.
21. Morigi M, Buelli S, Zanchi C, Longaretti L, Macconi D, Benigni A, Moioli D, Remuzzi G, Zoja C: Shigatoxin-induced endothelin-1 expression in cultured podocytes autocrinally mediates actin remodeling. Am J Pathol 2006;169:1965-1975.
22. Collino F, Bussolati B, Gerbaudo E, Marozio L, Pelissetto S, Benedetto C, Camussi G:Preeclamptic sera induce nephrin shedding from podocytes through endothelin-1 release by endothelial glomerular cells. Am J Physiol Renal Physiol 2008;294:F1185-1194.
23. Tharaux PL, Chatziantoniou C, Casellas D, Fouassier L, Ardaillou R, Dussaule JC:Vascular endothelin-1 gene expression and synthesis and effect on renal type I collagen synthesis and nephroangiosclerosis during nitric oxide synthase inhibition in rats. Circulation 1999;99:2185-2191.
24. Dussaule JC, Tharaux PL, Boffa JJ, Fakhouri F, Ardaillou R, Chatziantoniou C:Mechanisms mediating the renal profibrotic actions of vasoactive peptides in transgenic mice. J Am Soc Nephrol 2000;11(Suppl 16):S124-S128.
25. Berthold H, Munter K, Just A, Kirchheim HR, Ehmke H: Contribution of endothelin to renal vascular tone and autoregulation in the conscious dog. Am J Physiol 1999;276:F417-F424.
26. Qiu C, Samsell L, Baylis C: Actions of endogenous endothelin on glomerular hemodynamics in the rat. Am J Physiol 1995;269:R469-R473.
27. Tsuchiya K, Naruse M, Sanaka T, Naruse K, Zeng ZP, Nitta K, Demura H, Shizume K, Sugino N: Renal and hemodynamic effects of endothelin in anesthetized dogs. Am J Hypertens 1990;3:792-795.
28. Kon V, Yoshioka T, Fogo A, Ichikawa I:Glomerular actions of endothelin in vivo. J Clin Invest 1989;83:1762-1767.
29. Bakris GL, Fairbanks R, Traish AM: Arginine vasopressin stimulates human mesangial cell production of endothelin. J Clin Invest 1991;87:1158-1164.
30. Simonson MS, Dunn MJ: Endothelin-1 stimulates contraction of rat glomerular mesangial cells and potentiates betaadrenergic-mediated cyclic adenosine monophosphate accumulation. J Clin Invest 1990;85:790-797.
31. Simonson MS, Wann S, Mene P, Dubyak GR, Kester M, Dunn MJ: Endothelin-1 activates the phosphoinositide cascade in cultured glomerular mesangial cells. J Cardiovasc Pharmacol 1989;13(Suppl 5):S80-S83, discussion S84.
32. Badr KF, Murray JJ, Breyer MD, Takahashi K, Inagami T, Harris RC: Mesangial cell, glomerular and renal vascular responses to endothelin in the rat kidney. Elucidation of signal transduction pathways. J Clin Invest 1989;83:336-342.
33. Mann JF, Green D, Jamerson K, Ruilope LM, Kuranoff SJ, Littke T, Viberti G: Avosentan for overt diabetic nephropathy. J Am Soc Nephrol 2010;21:527-535.
34. Wenzel RR, Littke T, Kuranoff S, Jurgens C, Bruck H, Ritz E, Philipp T, Mitchell A:Avosentan reduces albumin excretion in diabetics with macroalbuminuria. J Am Soc Nephrol 2009;20:655-664.
35. Kohan DE, Pritchett Y, Molitch M, Wen S, Garimella T, Audhya P, Andress DL:Addition of atrasentan to renin-angiotensin system blockade reduces albuminuria in diabetic nephropathy. J Am Soc Nephrol 2011;22:763-772.
36. Opocensky M, Kramer HJ, Backer A, Vernerova Z, Eis V, Cervenka L, Certikova Chabova V, Tesar V, Vaneckova I: Late-onset endothelin-A receptor blockade reduces podocyte injury in homozygous Ren-2 rats despite severe hypertension. Hypertension 2006;48:965-971.
37. Whitworth CE, Veniant MM, Firth JD, Cumming AD, Mullins JJ: Endothelin in the kidney in malignant phase hypertension. Hypertension 1995;26:925-931.
38. Sventek P, Li JS, Grove K, Deschepper CF, Schiffrin EL: Vascular structure and expression of endothelin-1 gene in L-NAMEtreated spontaneously hypertensive rats. Hypertension 1996;27:49-55.
39. Petruzziello TN, Mawji IA, Khan M, Marsden PA: Verotoxin biology: molecular events in vascular endothelial injury. Kidney Int Suppl 2009:S17-S19.
40. Bitzan MM, Wang Y, Lin J, Marsden PA:Verotoxin and ricin have novel effects on preproendothelin-1 expression but fail to modify nitric oxide synthase (ecNOS) expression and NO production in vascular endothelium. J Clin Invest 1998;101:372-382.
41. Nangaku M, Yamada K, Gariepy CE, Miyata T, Inagi R, Kurokawa K, Yanagisawa M, Fujita T, Johnson RJ: ET(B) receptor protects the tubulointerstitium in experimental thrombotic microangiopathy. Kidney Int 2002;62:922-928.
42. Sabaa N, de Franceschi L, Bonnin P, Castier Y, Malpeli G, Debbabi H, Galaup A, Maier-Redelsperger M, Vandermeersch S, Scarpa A, Janin A, Levy B, Girot R, Beuzard Y, Leboeuf C, Henri A, Germain S, Dussaule JC, Tharaux PL: Endothelin receptor antagonism prevents hypoxia-induced mortality and morbidity in a mouse model of sickle-cell disease. J Clin Invest 2008;118:1924-1933.
43. Mouthon L, Mehrenberger M, Teixeira L, Fakhouri F, Berezne A, Guillevin L, Noel LH: Endothelin-1 expression in scleroderma renal crisis. Hum Pathol 2011;42:95-102.
44. Nakamura T, Ebihara I, Fukui M, Osada S, Tomino Y, Masaki T, Goto K, Furuichi Y, Koide H: Renal expression of mRNAs for endothelin-1, endothelin-3 and endothelin receptors in NZB/W F1 mice. Ren Physiol Biochem 1993;16:233-243.
45. Nakamura T, Ebihara I, Tomino Y, Koide H: Effect of a specific endothelin A receptor antagonist on murine lupus nephritis. Kidney Int 1995;47:481-489.
46. Yoshio T, Masuyama J, Mimori A, Takeda A, Minota S, Kano S: Endothelin-1 release from cultured endothelial cells induced by sera from patients with systemic lupus erythematosus. Ann Rheum Dis 1995;54:361-365.
47. Barton M: Reversal of proteinuric renal disease and the emerging role of endothelin. Nat Clin Pract Nephrol 2008;4:490-501.
48. Luft FC, Mervaala E, Muller DN, Gross V, Schmidt F, Park JK, Schmitz C, Lippoldt A, Breu V, Dechend R, Dragun D, Schneider W, Ganten D, Haller H: Hypertensioninduced end-organ damage: a new transgenic approach to an old problem. Hypertension 1999;33:212-218.
49. Neuhofer W, Pittrow D: Endothelin receptor selectivity in chronic kidney disease:rationale and review of recent evidence. Eur J Clin Invest 2009;39(Suppl 2):50-67.
50. Kohan DE: Endothelin, hypertension and chronic kidney disease: new insights. Curr Opin Nephrol Hypertens 2010;19:134-139.
51. Barton M: Therapeutic potential of endothelin receptor antagonists for chronic proteinuric renal disease in humans. Biochim Biophys Acta 2010;1802:1203-1213.
52. Davenport AP, Nunez DJ, Brown MJ:Binding sites for 125I-labelled endothelin-1 in the kidneys: differential distribution in rat, pig and man demonstrated by using quantitative autoradiography. Clin Sci 1989;77:129-131.
53. Rebibou JM, He CJ, Delarue F, Peraldi MN, Adida C, Rondeau E, Sraer JD: Functional endothelin 1 receptors on human glomerular podocytes and mesangial cells. Nephrol Dial Transplant 1992;7:288-292.
54. Lopez-Ongil S, Diez-Marques ML, Griera M, Rodriguez-Puyol M, Rodriguez-Puyol D:Crosstalk between mesangial and endothelial cells: angiotensin II down-regulates endothelin-converting enzyme 1. Cell Physiol Biochem 2005;15:135-144.
55. Fogo AB: Animal models of FSGS: lessons for pathogenesis and treatment. Semin Nephrol 2003;23:161-171.
56. Diamond JR, Karnovsky MJ: Focal and segmental glomerulosclerosis following a single intravenous dose of puromycin aminonucleoside. Am J Pathol 1986;122:481-487.
57. Kasinath BS, Fried TA, Davalath S, Marsden PA: Glomerular epithelial cells synthesize endothelin peptides. Am J Pathol 1992;141:279-283.
58. Cybulsky AV, Stewart DJ, Cybulsky MI:Glomerular epithelial cells produce endothelin-1. J Am Soc Nephrol 1993;3:1398-1404.
59. Gagliardini E, Corna D, Zoja C, Sangalli F, Carrara F, Rossi M, Conti S, Rottoli D, Longaretti L, Remuzzi A, Remuzzi G, Benigni A: Unlike each drug alone, lisinopril if combined with avosentan promotes regression of renal lesions in experimental diabetes. Am J Physiol Renal Physiol 2009;297:F1448-F1456.
60. Megyesi J, Price PM, Tamayo E, Safirstein RL: The lack of a functional p21(WAF1/CIP1) gene ameliorates progression to chronic renal failure. Proc Natl Acad Sci USA 1999;96:10830-10835.
61. Di Cunto F, Topley G, Calautti E, Hsiao J, Ong L, Seth PK, Dotto GP: Inhibitory function of p21Cip1/WAF1 in differentiation of primary mouse keratinocytes independent of cell cycle control. Science 1998;280:1069-1072.
62. Dijkman H, Smeets B, van der Laak J, Steenbergen E, Wetzels J: The parietal epithelial cell is crucially involved in human idiopathic focal segmental glomerulosclerosis. Kidney Int 2005;68:1562-1572.
63. Appel D, Kershaw DB, Smeets B, Yuan G, Fuss A, Frye B, Elger M, Kriz W, Floege J, Moeller MJ: Recruitment of Podocytes from Glomerular Parietal Epithelial Cells. J Am Soc Nephrol 2009;20:333-343.
64. Smeets B, Angelotti ML, Rizzo P, Dijkman H, Lazzeri E, Mooren F, Ballerini L, Parente E, Sagrinati C, Mazzinghi B, Ronconi E, Becherucci F, Benigni A, Steenbergen E, Lasagni L, Remuzzi G, Wetzels J, Romagnani P: Renal progenitor cells contribute to hyperplastic lesions of podocytopathies and crescentic glomerulonephritis. J Am Soc Nephrol 2009;20:2593-2603.
65. Yoshimura A, Iwasaki S, Inui K, Ideura T, Koshikawa S, Yanagisawa M, Masaki T: Endothelin-1 and endothelin B type receptor are induced in mesangial proliferative nephritis in the rat. Kidney Int 1995;48:1290-1297.
66. Gomez-Garre D, Largo R, Liu XH, Gutierrez S, Lopez-Armada MJ, Palacios I, Egido J: An orally active ETA/ETB receptor antagonist ameliorates proteinuria and glomerular lesions in rats with proliferative nephritis. Kidney Int 1996;50:962-972.
67. Nicolaidou P, Georgouli H, Matsinos Y, Psychou F, Messaritaki A, Gourgiotis D, Zeis P: Endothelin-1 in children with acute poststreptococcal glomerulonephritis and hypertension. Pediatr Int 2003;45:35-38.
68. Kisanuki YY, Emoto N, Ohuchi T, Widyantoro B, Yagi K, Nakayama K, Kedzierski RM, Hammer RE, Yanagisawa H, Williams SC, Richardson JA, Suzuki T, Yanagisawa M: Low blood pressure in endothelial cell-specific endothelin 1 knockout mice. Hypertension 2010;56:121-128.
69. Herman WH, Emancipator SN, Rhoten RL, Simonson MS: Vascular and glomerular expression of endothelin-1 in normal human kidney. Am J Physiol 1998;275:F8-F17.
70. Frank K, Zeier M, Gross ML, Waldherr R, Ritz E, Amann K: Comprehensive immunohistological analysis of the endothelin system in human kidney grafts. Nephrol Dial Transplant 2006;21:1365-1372.
71. Orth SR, Odoni G, Amann K, Strzelczyk P, Raschack M, Ritz E: The ET(A) receptor blocker LU 135252 prevents chronic transplant nephropathy in the 'Fisher to Lewis' model. J Am Soc Nephrol 1999;10:387-391.
72. Lehrke I, Waldherr R, Ritz E, Wagner J:Renal endothelin-1 and endothelin receptor type B expression in glomerular diseases with proteinuria. J Am Soc Nephrol 2001;12:2321-2329.
73. Rastaldi MP, Tunesi S, Ferrario F, Indaco A, Zou H, Napodano P, D'Amico G:Transforming growth factor-beta, endothelin-1, and c-fos expression in necrotizing/crescentic IgA glomerulonephritis. Nephrol Dial Transplant 1998;13:1668-1674.
74. Nakamura T, Ebihara I, Shirato I, Fukui M, Tomino Y, Koide H: Endothelin-1 mRNA expression by peripheral blood monocytes in IgA nephropathy. Lancet 1993;342:1147-1148.
75. Chen HC, Guh JY, Chang JM, Lai YH:Differential effects of FMLP-activated neutrophils from patients with IgA nephropathy enhanced endothelin 1 production of glomerular mesangial cells. Nephron 2001;89:274-279.
76. Nakamura T, Ebihara I, Fukui M, Tomino Y, Koide H: Effect of a specific endothelin receptor A antagonist on glomerulonephritis of ddY mice with IgA nephropathy. Nephron 1996;72:454-460.
77. Nett PC, Teixeira MM, Candinas D, Barton M: Recent developments on endothelin antagonists as immunomodulatory drugs -from infection to transplantation medicine. Recent Pat Cardiovasc Drug Discov 2006;1:265-276.
78. Saleh MA, Boesen EI, Pollock JS, Savin VJ, Pollock DM: Endothelin receptor A-specific stimulation of glomerular inflammation and injury in a streptozotocin-induced rat model of diabetes. Diabetologia 2011;54:979-988.
79. Sasser JM, Sullivan JC, Hobbs JL, Yamamoto T, Pollock DM, Carmines PK, Pollock JS:Endothelin A receptor blockade reduces diabetic renal injury via an anti-inflammatory mechanism. J Am Soc Nephrol 2007;18:143-154.
80. Boesen EI, Sasser JM, Saleh MA, Potter WA, Woods M, Warner TD, Pollock JS, Pollock DM: Interleukin-1beta, but not interleukin-6, enhances renal and systemic endothelin production in vivo. Am J Physiol Renal Physiol 2008;295:F446-453.
81. Ebihara I, Nakamura T, Tomino Y, Koide H: Effect of a specific endothelin receptor A antagonist on murine lupus nephritis and IgA nephropathy. Contrib Nephrol 1996;118:155-163.
82. Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, Pulido T, Frost A, Roux S, Leconte I, Landzberg M, Simonneau G:Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002;346:896-903.
83. Cozzi F, Montisci R, Marotta H, Bobbo F, Durigon N, Ruscazio M, Sfriso P, Iliceto S, Todesco S: Bosentan therapy of pulmonary arterial hypertension in connective tissue diseases. Eur J Clin Invest 2006;36(Suppl 3):49-53.
84. Suzuki E, Kyozuka H, Nishida T, Kanno T, Ohira H: Systemic lupus erythematosus, complicated with refractory skin ulcers, treated successfully with bosentan. Mod Rheumatol 2009;19:447-451.
85. Julkunen H, Saijonmaa O, Gronhagen-Riska C, Teppo AM, Fyhrquist F: Raised plasma concentrations of endothelin-1 in systemic lupus erythematosus. Ann Rheum Dis 1991;50:526-527.
86. Karet FE, Davenport AP: Localization of endothelin peptides in human kidney. Kidney Int 1996;49:382-387.
87. Dhaun N, Lilitkarntakul P, Macintyre IM, Muilwijk E, Johnston NR, Kluth DC, Webb DJ, Goddard J: Urinary endothelin-1 in chronic kidney disease and as a marker of disease activity in lupus nephritis. Am J Physiol Renal Physiol 2009;296:F1477-1483.
88. Skolovsky M, Galron R, Kloog Y, Bdolah A, Indig FE, Blumberg S, Fleminger G:Endothelins are more sensitive than sarafotoxins to neutral endopeptidase: possible physiological significance. Proc Natl Acad Sci USA 1990;87:4702-4706.
89. Edwards RM, Pullen M, Nambi P:Distribution of neutral endopeptidase activity along the rat and rabbit nephron. Pharmacology 1999;59:45-50.
90. Janas J, Sitkiewicz D, Pulawska MF, Warnawin K, Janas RM: Purification of endothelin-1-inactivating peptidase from the rat kidney. J Hypertens 1994;12:375-382.
91. Chen CL, Fang HC, Chou KJ, Lee JC, Lee PT, Chung HM, Wang JS: Increased endothelin 1 expression in adult-onset minimal change nephropathy with acute renal failure. Am J Kidney Dis 2005;45:818-825.
92. Orisio S, Benigni A, Bruzzi I, Corna D, Perico N, Zoja C, Benatti L, Remuzzi G: Renal endothelin gene expression is increased in remnant kidney and correlates with disease progression. Kidney Int 1993;43:354-358.
93. Benigni A, Zoja C, Corna D, Orisio S, Longaretti L, Bertani T, Remuzzi G: A specific endothelin subtype A receptor antagonist protects against injury in renal disease progression. Kidney Int 1993;44:440-444.
94. Nakamura T, Fukui M, Ebihara I, Osada S, Takahashi T, Tomino Y, Koide H: Effects of a low-protein diet on glomerular endothelin family gene expression in experimental focal glomerular sclerosis. Clin Sci (Lond) 1995;88:29-37.
95. Terzi F, Henrion D, Colucci-Guyon E, Federici P, Babinet C, Levy BI, Briand P, Friedlander G: Reduction of renal mass is lethal in mice lacking vimentin. Role of endothelin-nitric oxide imbalance. J Clin Invest 1997;100:1520-1528.
96. Hocher B, Lun A, Priem F, Neumayer HH, Raschack M: Renal endothelin system in diabetes:comparison of angiotensin-converting enzyme inhibition and endothelin-A antagonism. J Cardiovasc Pharmacol 1998;31(Suppl 1):S492-S495.
97. Ding SS, Qiu C, Hess P, Xi JF, Zheng N, Clozel M: Chronic endothelin receptor blockade prevents both early hyperfiltration and late overt diabetic nephropathy in the rat. J Cardiovasc Pharmacol 2003;42:48-54.
98. Wolkart G, Stessel H, Saad Z, Kirchengast M, Brunner F: Cardioprotective effects of atrasentan, an endothelin-A receptor antagonist, but not of nitric oxide in diabetic mice with myocyte-specific overexpression of endothelial nitric oxide synthase. Br J Pharmacol 2006;148:671-681.
99. Barton M, Mullins JJ, Bailey MA, Kretzler M:Role of endothelin receptors for renal protection and survival in hypertension: waiting for clinical trials. Hypertension 2006;48:834-837.
100. Ohta K, Hirata Y, Shichiri M, Kanno K, Emori T, Tomita K, Marumo F: Urinary excretion of endothelin-1 in normal subjects and patients with renal disease. Kidney Int 1991;39:307-311.
101. Tharaux PL, Hagege I, Placier S, Vayssairat M, Kanfer A, Girot R, Dussaule JC: Urinary endothelin-1 as a marker of renal damage in sickle cell disease. Nephrol Dial Transplant 2005;20:2408-2413.
102. Genovese G, Friedman DJ, Ross MD, Lecordier L, Uzureau P, Freedman BI, Bowden DW, Langefeld CD, Oleksyk TK, Uscinski Knob AL, Bernhardy AJ, Hicks PJ, Nelson GW, Vanhollebeke B, Winkler CA, Kopp JB, Pays E, Pollak MR: Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science 2010;329:841-845.
103. Dhaun N, Macintyre IM, Melville V, Lilitkarntakul P, Johnston NR, Goddard J, Webb DJ: Blood pressure-independent reduction in proteinuria and arterial stiffness after acute endothelin-A receptor antagonism in chronic kidney disease. Hypertension 2009;54:113-119.
104. Dhaun N, Macintyre IM, Melville V, Lilitkarntakul P, Johnston NR, Goddard J, Webb DJ: Effects of endothelin receptor antagonism relate to the degree of reninangiotensin system blockade in chronic proteinuric kidney disease. Hypertension 2009;54:e19-e20.
105. Deng LY, Schiffrin EL: Endothelin-1 gene expression in blood vessels and kidney of spontaneously hypertensive rats (SHR), L-NAME-treated SHR, and renovascular hypertensive rats. J Cardiovasc Pharmacol 1998;31(Suppl 1):S380-383.